Overview & Collaborations Opportunities
We are focused on science-based in silico predictive discovery of biologics – proteins and antibody targets for oncology and immunology. Our discoveries are based on more than a decade of interdisciplinary research, with more than 70 publications in peer-reviewed journals since 2001, leading to over 12 discovery platforms announced so far. We model key biological phenomena such as alternative splicing, protein cleavage and protein interacting segments; we integrate and analyze vast quantities of experimental data, both public and proprietary, and systematically predict and select novel product candidates for oncology and immunology. We form R&D collaborations with biopharmaceutical and biotechnology companies to discover novel drug candidates that are of interest to partners (e.g., inhibition of a target of interest and discovery of novel family members). We also form co-development collaborations around discoveries already in our portfolio, aiming to further advance these programs towards IND, and provide partners with exclusive licenses for further clinical development and commercialization.
For more information about partnering with Compugen, please contact